Introduction {#Sec1}
============

Women and men show marked differences both in the onset of heart failure and in established chronic heart failure \[[@CR1], [@CR2]\]. We recently showed that clinical characteristics of men and women admitted for acute heart failure are also different \[[@CR3]\]. Relative to men, women typically more often show features such as hypertension, atrial fibrillation and preserved left ventricular ejection fraction, whereas men usually present with ischemic heart disease, history of myocardial infarction, reduced left ventricular ejection fraction, and specific medical and device treatment \[[@CR3]\].

In previous studies, women admitted for acute heart failure received lower oral and intravenous diuretic doses, had fewer dose increases, lost less body weight during hospitalization, and had a longer length of hospitalization compared with men \[[@CR3], [@CR4]\]. However, no studies have specifically focused on differences in dyspnea relief and changes in general wellbeing between men and women admitted for acute heart failure.

Here, we investigate sex differences in early and persistent dyspnea relief as well as additional efficacy endpoints, and analyzed patient features and heart failure characteristics in men and women hospitalized for acute heart failure enrolled in the RELAX-AHF study \[[@CR5]\]. The RELAX-AHF study tested the effects of serelaxin, a recombinant form of the natural hormone human relaxin 2, vs. placebo on dyspnea relief on top of standard of care \[[@CR5]\], and provided insights into specific effects of serelaxin in acute heart failure \[[@CR6], [@CR7]\].

Patients and methods {#Sec2}
====================

Study design, population and treatment {#Sec3}
--------------------------------------

The RELAX-AHF study was a multi-center, double-blind, randomized, controlled trial, comparing the intravenous administration of serelaxin for up to 48 h vs. placebo on top of standard of care. Patients were randomized within the initial 16 h of hospital admission for AHF with congestion and dyspnea, additionally having elevated natriuretic peptide levels, mild to moderate renal dysfunction, and systolic blood pressure \>125 mmHg. Notably, patient-reported dyspnea improvement was evaluated by the two primary efficacy endpoints of the RELAX-AHF study: first, change from baseline to day 5 in the visual analog scale area under the curve (VAS AUC) and, second, the proportion of patients with moderate or marked dyspnea improvement as indicated by Likert scale ratings at 6, 12 and 24 h (all three), both analyzed by intention to treat \[[@CR5]\]. The VAS was a 0--100-mm long scale on which each patient marked the level of dyspnea and the distance from the 0-level of the scale was measured. VAS appropriately allows quantification of within-subject changes of repeated measurements as it has the sensitivity required to measure changes. The 7-item Likert scale is a psychometric instrument for the grading of dyspnea. Patients were asked to rate the degree of improvement in response to therapy within the spectrum of categories ranging from markedly better to markedly worse. Notably, for the patients with available dyspnea Likert assessments, those following death, worsening heart failure or heart failure/renal failure rehospitalization event were imputed as the worst score of the Likert scale as 'markedly worse' (worse Likert score = −3); for the "Time to Moderately or Markedly Better Dyspnea Through Day 5" analyses, for patients who died, had worsening heart failure or re-hospitalization due to heart failure, the day was set to 6 days.

Ethics {#Sec4}
------

The RELAX-AHF study was approved by all local Ethics Committees and complied with the Declaration of Helsinki guidelines. Written informed consent was obtained from all patients.

Statistical analyses {#Sec5}
--------------------

1161 patients were randomized in RELAX-AHF \[the Intent-to-Treat (ITT) population\]. For outcomes with complete data, the analysis included all randomized patients (*n* = 1161). For other outcomes, cases with missing outcome data were omitted from the analysis under an assumption of missing at random. Missing values in baseline covariates were imputed using treatment-specific medians for continuous variables and treatment-specific modal values for categorical variables. The criterion for statistical significance is *p* ≤ 0.05 two-tailed for all analyses. Patient baseline characteristics, symptomatic response, diuretic doses, treatment response, and post-discharge outcomes were compared by sex using *t* tests for continuous variables, Chi squared tests or Fisher's exact tests for categorical variables, and log-rank tests for time-to-event outcomes. Effects of treatment by sex interaction on clinical outcomes were examined using multiple linear regression models for continuous endpoints, logistic regression models for categorical endpoints, and Cox proportional hazards models for time-to-event endpoints. Three-way interaction effects of sex, treatment, and EF status on clinical outcomes were also examined using the same approach. A multi-variable logistic regression model was used to assess the association between moderately or markedly better dyspnea on the Likert scale at 6, 12 and 24 h and selected baseline characteristics, including sex, HFpEF status as defined by ESC-guideline criteria \[[@CR8]\], age, pulse pressure, heart rate, and loop diuretic dose. The effect of treatment by sex interaction on markedly or moderately improved dyspnea at each time point (6, 12 and 24 h) was also estimated using logistic regression models. Repeated measures ANOVA models were used to estimate mean changes in biomarkers (hs-troponin-T, NT-proBNP and cystatin-C) from baseline through day 14, mean changes in patient-reported dyspnea according to visual analog scale from baseline to day 5, and mean total daily dose of IV diuretics (mg) from day 1 to day 5, stratified by treatment and sex. A linear regression model was used to estimate the effects of treatment, sex and their interaction on total dose of IV diuretics from day 1 to day 5. Fisher's exact tests were used to assess the association between treatment and physician-assessed signs and symptoms of congestion at day 2 for each sex. Effects of treatment by sex interaction on physician-assessed signs and symptoms of congestion at day 2 were evaluated using proportional-odds logistic regression models. Kaplan--Meier survival curves for CV mortality through day 180 were generated for all sex and treatment combinations, and compared using log-rank tests. A Cox proportional hazard model was used to examine the treatment effect by sex.

Analyses were performed by the Statistical Analysis Center at Columbia University.

Results {#Sec6}
=======

Baseline characteristics {#Sec7}
------------------------

Details of baseline patient characteristics are shown in Table [1](#Tab1){ref-type="table"}. The RELAX-AHF study comprised 725 men and 436 women. Women were on average 6 years older, had about 10% higher LVEF and a lower proportion of LVEF \<40%, and had less frequent ischemic heart disease or a history of chronic heart failure one month prior. Before hospitalization, women had lower NYHA class symptoms and they more often had hypertension, while less frequently being cigarette smokers or showing peripheral vascular disease, asthma, bronchitis, or COPD, myocardial infarction and history of CRT or ICD procedures and implanted devices. Women less often received oral loop diuretics 30 days before study entry and were more often treated with digoxin. Plasma levels of hemoglobin, creatinine, uric acid, troponin and estimated glomerular filtration rate were lower in women, whereas they had higher levels of total cholesterol. There were no significant sex differences in clinical variables or congestion.Table 1Baseline characteristics by sex (*n* = 1161)VariablesTotal^a^ (*n* = 1161)Men^a^ (*n* = 725)Women^a^ (*n* = 436)*p* value^b^Demographics and HF characteristics Age (years)72.0 (11.2)69.8 (11.7)75.8 (9.2)\<0.0001 \[S\] Serelaxin administration (%)581 (50.0%)368 (50.8%)213 (48.9%)0.5295 \[2\] White1096 (94.4%)680 (93.8%)416 (95.4%)0.2450 \[2\] Geographic region0.0001 \[2\]  Eastern EU562 (48.4%)315 (43.4%)247 (56.7%)  Western EU204 (17.6%)144 (19.9%)60 (13.8%)  South America71 (6.1%)45 (6.2%)26 (6.0%)  North America114 (9.8%)85 (11.7%)29 (6.7%)  Israel210 (18.1%)136 (18.8%)74 (17.0%) US-Like^c^786 (67.7%)540 (74.5%)246 (56.4%)\<0.0001 \[2\] Left ventricular EF (%)38.6 (14.6)35.1 (13.2)44.7 (14.9)\<0.0001 \[S\] EF \<40%598 (54.8%)446 (64.8%)152 (37.7%)\<0.0001 \[2\] Ischemic heart disease603 (51.9%)419 (57.8%)184 (42.2%)\<0.0001 \[2\] Time to randomization (h)7.9 (4.6)7.7 (4.8)8.2 (4.4)0.0384 \[1\] CHF 1 month prior861 (74.2%)557 (76.8%)304 (69.7%)0.0074 \[2\] HF hospitalization past year397 (34.2%)260 (35.9%)137 (31.4%)0.1225 \[2\] NYHA class 30 days before admission0.0014 \[2\]  I323 (28.1%)186 (25.8%)137 (31.8%)  II304 (26.4%)174 (24.2%)130 (30.2%)  III389 (33.8%)268 (37.2%)121 (28.1%)  IV135 (11.7%)92 (12.8%)43 (10.0%)Clinical variables Body mass index (kg/m^2^)29.3 (5.7)29.3 (5.3)29.3 (6.3)0.8964 \[S\] Syst. blood pressure (mmHg)142.2 (16.6)141.2 (16.5)143.8 (16.7)0.0110 \[1\] Diast. blood pressure (mmHg)79.0 (14.2)79.8 (14.0)77.7 (14.5)0.0125 \[1\] Heart rate (beats/min)79.7 (14.9)79.1 (14.5)80.6 (15.6)0.1093 \[1\] Respiratory rate (breaths/min)21.9 (4.6)21.7 (4.6)22.3 (4.6)0.0299 \[1\]Congestion at baseline Edema910 (78.9%)578 (80.4%)332 (76.3%)0.1010 \[2\] Orthopnea1106 (95.8%)689 (95.8%)417 (95.9%)0.9773 \[2\] JVP850 (75.5%)533 (76.0%)317 (74.6%)0.5845 \[2\] Dyspnea on exertion1136 (99.6%)708 (99.7%)428 (99.5%)0.6351 \[3\] Dyspnea by VAS44.2 (20.0)44.7 (19.9)43.4 (20.1)0.2839 \[1\] Rales1095 (94.8%)679 (94.3%)416 (95.6%)0.3249 \[2\]Comorbidities Hypertension1006 (86.6%)602 (83.0%)404 (92.7%)\<0.0001 \[2\] Hyperlipidemia617 (53.1%)405 (55.9%)212 (48.6%)0.0167 \[2\] Diabetes mellitus551 (47.5%)347 (47.9%)204 (46.8%)0.7229 \[2\] Cigarette smoking153 (13.2%)127 (17.5%)26 (6.0%)\<0.0001 \[2\] Stroke or other cerebrovascular event157 (13.5%)101 (13.9%)56 (12.8%)0.5999 \[2\] Peripheral vascular disease155 (13.4%)115 (15.9%)40 (9.2%)0.0012 \[2\] Asthma, bronchitis, or COPD184 (15.8%)138 (19.0%)46 (10.6%)0.0001 \[2\] Atrial fibrillation at screening479 (41.3%)284 (39.2%)195 (44.8%)0.0608 \[2\] History of atrial fibrillation or flutter602 (51.9%)354 (48.8%)248 (56.9%)0.0078 \[2\] History of CRT or ICD procedures294 (25.3%)218 (30.1%)76 (17.4%)\<0.0001 \[2\] Myocardial infarction403 (34.7%)286 (39.4%)117 (26.8%)\<0.0001 \[2\] Depression60 (5.2%)34 (4.7%)26 (6.0%)0.3425 \[2\]Devices Pacemaker121 (10.4%)70 (9.7%)51 (11.7%)0.2701 \[2\] Implantable cardiac defibrillator154 (13.3%)136 (18.8%)18 (4.1%)\<0.0001 \[2\] Biventricular pacing113 (9.7%)96 (13.2%)17 (3.9%)\<0.0001 \[2\]Medication ACE inhibitor633 (54.5%)392 (54.1%)241 (55.3%)0.6894 \[2\] ACEi or ARBs788 (67.9%)492 (67.9%)296 (67.9%)0.9922 \[2\] Angiotensin-receptor blocker185 (15.9%)112 (15.4%)73 (16.7%)0.5594 \[2\] Beta-blocker794 (68.4%)507 (69.9%)287 (65.8%)0.1451 \[2\] Aldosterone antagonist365 (31.4%)240 (33.1%)125 (28.7%)0.1151 \[2\] Oral loop diuretic 30 days prior44.7 (65.2)50.5 (72.3)34.9 (49.6)\<0.0001 \[S\] Digoxin228 (19.6%)116 (16.0%)112 (25.7%)\<0.0001 \[2\] Nitrates at randomization81 (7.0%)42 (5.8%)39 (8.9%)0.0412 \[2\]Baseline laboratory data Sodium (mmol/L)140.82 (3.59)140.76 (3.60)140.93 (3.57)0.4183 \[1\] Phosphate (mmol/L)1.19 (0.32)1.18 (0.36)1.20 (0.23)0.3547 \[S\] Calcium (mmol/L)2.26 (0.15)2.26 (0.16)2.27 (0.14)0.8622 \[S\] Hemoglobin (g/dL)12.79 (1.86)13.11 (1.89)12.27 (1.68)\<0.0001 \[S\] White blood cell count (×10/L)8.179 (2.843)8.022 (2.637)8.439 (3.142)0.0243 \[S\] Lymphocyte (%)18.17 (7.81)18.50 (7.81)17.64 (7.78)0.0803 \[1\] Potassium (mmol/L)4.27 (0.63)4.31 (0.64)4.21 (0.61)0.0098 \[1\] Creatinine (μmol/L)116.58 (33.15)126.28 (32.81)100.58 (26.94)\<0.0001 \[S\] Uric acid (μmol/L)475.8 (135.9)488.1 (137.7)455.4 (130.6)\<0.0001 \[1\] Troponin T (μg/L^d^)0.035 (0.033, 0.037)0.037 (0.035, 0.040)0.031 (0.029, 0.034)0.0015 \[S\] BUN (mmol/L)9.78 (4.03)10.01 (3.96)9.40 (4.10)0.0132 \[1\] Cystatin-C (mg/L^d^)1.45 (1.43, 1.48)1.46 (1.43, 1.49)1.44 (1.40, 1.48)0.4950 \[1\] Alanine aminotransferase (U/L^d^)23.5 (22.7, 24.4)23.8 (22.7, 25.0)23.1 (21.8, 24.5)0.4078 \[1\] NT-proBNP (ng/L^d^)5054 (4795, 5326)4936 (4615, 5279)5253 (4830, 5714)0.2579 \[1\] eGFR (mL/min per 1.73 m^2^)53.49 (13.03)54.81 (12.84)51.32 (13.06)\<0.0001 \[1\] Total cholesterol (mmol/L)4.09 (1.17)3.97 (1.13)4.30 (1.20)\<0.0001 \[1\] Glucose (mmol/L)7.75 (3.57)7.62 (3.48)7.96 (3.71)0.1202 \[1\] Albumin (g/L)40.23 (4.33)40.28 (4.57)40.15 (3.91)0.6229 \[S\]^a^Mean (SD), or geometric mean (95% CI) if log transformed, for continuous variables, *n* (%) for categorical variables (% based on total number of patients with a non-missing value of the characteristic)^b^Based on *t* test \[1\], Chi squared test \[2\], Fisher's exact test \[3\], or the Satterthwaite method due to unequal variances in comparison groups \[S\]^c^US-Like in the analyses indicates Region 1 vs. Region 2. Region 1 includes patients from United States, France, The Netherlands, Israel, Spain, Germany, Italy, and Poland. Region 2 includes patients from Argentina, Hungary, and Romania^d^The following baseline laboratory variables have been log transformed: alanine aminotransferase, NT-proBNP, troponin T, cystatin-C

Symptomatic response by sex {#Sec8}
---------------------------

Details on the symptomatic response by sex are shown in Table [2](#Tab2){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}.Table 2Symptomatic response by sexTotal cohort^a^ (*n* = 1161)Men^a^ (*n* = 725)Women^a^ (*n* = 436)*p* value^b^Change from baseline VAS score (mm) Hour 69.55 (16.51)8.92 (16.21)10.60 (16.97)0.0933 \[1\] Hour 1214.20 (19.33)13.35 (19.74)15.63 (18.57)0.0518 \[1\] Day 118.74 (23.49)17.77 (23.35)20.35 (23.66)0.0701 \[1\] Day 222.35 (26.55)21.46 (27.02)23.82 (25.70)0.1420 \[1\] Day 525.94 (30.77)24.88 (31.02)27.68 (30.30)0.1334 \[1\] Day 1422.72 (34.52)22.01 (34.56)23.90 (34.46)0.3661 \[1\]Dyspnea VAS AUC (mm × h) Baseline to day 147786.82 (9333.49)7482.07 (9410.64)8293.56 (9192.12)0.1515 \[1\] Day 1 to day 52234.37 (2549.18)2137.14 (2566.48)2396.04 (2514.75)0.0938 \[1\] Day 1 to day 147489.24 (9077.60)7201.79 (9152.91)7967.23 (8940.94)0.1642 \[1\]Dyspnea markedly or moderately improved per Likert scale, *n* (%) Hour 6385 (33.6%)221 (31.0%)164 (38.0%)0.0156 \[2\] Hour 12544 (47.5%)313 (43.8%)231 (53.5%)0.0015 \[2\] Day 1751 (65.5%)443 (62.0%)308 (71.1%)0.0017 \[2\] Day 2850 (74.0%)510 (71.3%)340 (78.5%)0.0070 \[2\] Day 5915 (79.5%)555 (77.4%)360 (82.9%)0.0240 \[2\] Day 14857 (74.4%)523 (72.8%)334 (77.0%)0.1208 \[2\]General wellbeing, change from baseline in VAS score (mm) Hour 69.12 (16.48)8.63 (16.12)9.93 (17.06)0.1933 \[1\] Hour 1213.61 (18.85)13.04 (18.64)14.56 (19.19)0.1843 \[1\] Day 118.20 (22.72)17.45 (22.14)19.44 (23.63)0.1491 \[1\] Day 221.19 (25.77)20.47 (25.86)22.39 (25.61)0.2194 \[1\] Day 524.82 (30.43)23.50 (30.25)27.00 (30.64)0.0579 \[1\] Day 1421.35 (33.67)20.48 (33.28)22.81 (34.30)0.2530 \[1\]General wellbeing Likert score Hour 60.99 (1.11)0.94 (1.09)1.07 (1.12)0.0324 \[W\] Hour 121.31 (1.17)1.23 (1.19)1.44 (1.13)0.0018 \[W\] Day 11.60 (1.36)1.53 (1.36)1.71 (1.35)0.0040 \[W\] Day 21.75 (1.49)1.64 (1.55)1.91 (1.38)0.0012 \[W\] Day 51.84 (1.77)1.77 (1.83)1.97 (1.67)0.0434 \[W\] Day 141.56 (2.07)1.51 (2.11)1.65 (2.01)0.3751 \[W\]^a^Mean (SD) for continuous variables and *n* (%) for categorical variables (% based on total number of patients with a non-missing value of the characteristic)^b^Based on *t* tests \[1\] for continuous variables, and Chi squared tests \[2\] for categorical variables. Wilcoxon Rank Sum test \[W\] will be performed for general wellbeing Likert score Fig. 1Dyspnea Likert scale (**a**) and VAS AUC change (**b**) by treatment and sex

The change from baseline in dyspnea visual analog scale AUC to day 5 primary dyspnea endpoint did not vary by sex. However, there was a significantly higher proportion of women than men with moderate or marked dyspnea improvement measured by Likert scale during the first 24 h, which was the other primary endpoint in RELAX-AHF.

Likewise, the change from baseline in dyspnea visual analog scale score was not different in women compared to men. But there were consistently higher rates of women with markedly or moderately improved dyspnea per Likert scale and higher general wellbeing Likert score values in women, both through 24 h and through 5 days, respectively.

Diuretic doses, treatment response and post-discharge outcome by sex {#Sec9}
--------------------------------------------------------------------

Details on the diuretic doses, treatment response and post-discharge outcome by sex are shown in Table [3](#Tab3){ref-type="table"}. Women were treated with lower total IV and oral loop diuretic doses through day 5, respectively (Fig. [2](#Fig2){ref-type="fig"}), but dyspnea improved earlier moderately or markedly through day 5 in women. There were no relevant sex differences regarding changes in neither body weight nor relative body weight, worsening heart failure and outcome (Fig. [3](#Fig3){ref-type="fig"}), but women showed a trend towards longer ICU/CCU stays \[mean (SD), 4.05 (7.67) days vs. 3.51 (6.63) days, *p* = 0.0248\] and total initial hospital stays \[10.37 (9.62) days vs. 9.87 (9.17) days, *p* = 0.0258\] compared to men.Table 3Inotrope/vasoactive medication, diuretic doses, treatment response and post-discharge outcome by sexTotal cohort^a^ (*n* = 1161)Men^a^ (*n* = 725)Women^a^ (*n* = 436)*p* value^b^Inotrope/vasoactive medication All IV inotrope/vasoactive agents through day 5161 (13.9)93 (12.8)68 (15.6)0.1862 \[C\] Nitroglycerin127 (10.9)66 (9.1)61 (14.0)0.0098 \[C\]Diuretic doses and treatment response Total IV loop diuretic dose through day 5 (mg)187.21 (316.02)215.36 (364.91)140.76 (204.10)\<0.0001 \[S\] Total oral loop diuretic dose through day 5 (mg)187.70 (191.79)199.12 (204.05)168.86 (168.20)0.0067 \[S\]Treatment response Study day of moderately or markedly improved dyspnea through day 51.72 (2.00)1.87 (2.07)1.48 (1.85)0.0005 \[W\] Study day of worsening HF through day 55.65 (1.19)5.61 (1.25)5.71 (1.08)0.1395 \[W\] Worsening HF through day 14157 (13.56%)106 (14.67%)51 (11.71%)0.1522 \[L\]Change in bodyweight from baseline (kg) Day 1−1.48 (1.98)−1.56 (2.11)−1.33 (1.73)0.0433 \[S\] Day 2−2.03 (2.46)−2.13 (2.65)−1.87 (2.09)0.0752 \[S\] Day 5−2.86 (3.34)−2.93 (3.50)−2.76 (3.05)0.4210 \[S\] Day 14−3.31 (4.26)−3.49 (4.60)−3.02 (3.64)0.0642 \[S\]Relative change in bodyweight from baseline (%) Day 1−1.82 (2.38)−1.83 (2.44)−1.81 (2.28)0.8637 \[1\] Day 2−2.48 (2.90)−2.45 (2.97)−2.53 (2.80)0.6483 \[1\] Day 5−3.46 (3.91)−3.30 (3.84)−3.72 (4.01)0.0797 \[1\] Day 14−3.87 (4.75)−3.82 (4.89)−3.95 (4.53)0.6780 \[1\]Outcome Uncontrolled blood pressure^c^271 (23.3%)157 (21.7%)114 (26.1%)0.0798 \[C\] Length of ICU/CCU stay (days)3.71 (7.04)3.51 (6.63)4.05 (7.67)0.0248 \[W\] Length of initial hospital stay (days)10.06 (9.34)9.87 (9.17)10.37 (9.62)0.0258 \[W\] Days alive and out of hospital before day 3020.61 (6.64)20.68 (6.80)20.47 (6.38)0.1001 \[W\] Death or worsening HF or readmission to hospital for HF through day 30200 (17.30%)129 (17.87%)71 (16.34%)0.4556 \[L\] CV death or readmission to hospital for HF or renal failure through day 3083 (7.20%)50 (6.95%)33 (7.62%)0.6769 \[L\] CV death or readmission to hospital for HF or renal failure through day 30 after discharge92 (8.17%)55 (7.82%)37 (8.76%)0.5790 \[L\] All-cause death through day 3031 (2.68%)16 (2.22%)15 (3.46%)0.2100 \[L\] All-cause death or readmission to hospital for HF or renal failure through day 60154 (13.36%)97 (13.48%)57 (13.17%)0.9028 \[L\] CV death through day 18088 (7.68%)57 (7.98%)31 (7.20%)0.6484 \[L\] All-cause death through day 180107 (9.31%)68 (9.46%)39 (9.06%)0.8059 \[L\]^a^Mean (SD) for continuous variables; *n* (%) for categorical variables (% based on total number of patients with a non-missing value of the characteristic); and number of events (K-M%) for time-to-event variables^b^Based on Satterthwaite method \[S\] (if equal variance assumption violated) for continuous variables, Wilcoxon rank sum test \[W\] for count variables, Chi squared test \[C\] for categorical variables, and logrank test \[L\] for time-to-event variables^c^Uncontrolled blood pressure is defined as systolic \>150 mmHg or diastolic \>90 mmHg at day 2 and through day 5, or at time of discharge (if discharge time ≤day 5), whichever occurs first Fig. 2Total daily dose of IV diuretics from day 1 to day 5 stratified by treatment and sex Fig. 3Kaplan--Meier estimates for 180-day cardio-vascular mortality with numbers at risk by treatment and sex

Interaction analyses of differential effects by sex {#Sec10}
---------------------------------------------------

Physician-assessed signs and symptoms of congestion, such as dyspnea on exertion, orthopnea, edema or rales, did not vary by treatment and sex (Fig. [4](#Fig4){ref-type="fig"}). Moreover, women did not show different outcome than men in any of the analyzed endpoints. Neither did the relationship of sex with outcome vary by treatment with serelaxin, the presence of heart failure with preserved ejection fraction or both characteristics.Fig. 4Physician-assessed signs and symptoms of congestion at day 2 by treatment and sex

Effect of selected characteristics on early dyspnea improvement {#Sec11}
---------------------------------------------------------------

A multi-variable logistic regression model was built to assess the association between moderately or markedly better dyspnea on the Likert scale at 6, 12 and 24 h using selected baseline characteristics, such as sex, HF status, age, pulse pressure, heart rate, and loop diuretic dose as covariates (Table [4](#Tab4){ref-type="table"}). Male sex, age and total diuretic dose showed independent negative association with dyspnea improvement within 24 h.Table 4Association between moderately or markedly better dyspnea on the Likert scale at 6, 12 and 24 h and selected characteristics (*n* = 1076)CovariatesCoefficient (95% CI)Std. errOdds ratio (95% CI)*p* valueMale−0.5032 (−0.8053, −0.2011)0.15410.605 (0.447, 0.818)0.0011HFpEF (LVEF ≥50)−0.1579 (−0.4959, 0.1801)0.17250.854 (0.609, 1.197)0.3598Age−0.0200 (−0.0330, −0.0070)0.00660.980 (0.968, 0.993)0.0026Pulse pressure−0.0025 (−0.0113, 0.0064)0.00450.998 (0.989, 1.006)0.5861Heart rate0.0055 (−0.0041, 0.0152)0.00491.006 (0.996, 1.015)0.2607Total diuretic dose^a^−0.0031 (−0.0053, −0.0009)0.00110.997 (0.995, 0.999)0.0067Logistic regression model to estimate the relationship between the dependent variable and the covariates^a^Total diuretic dose is defined as IV loop diuretics dose + 0.5 × oral loop diuretics on day 1

Changes in biomarkers {#Sec12}
---------------------

The changes of hs-troponin-T, NT-proBNP, and cystatin-C from baseline to day 2, 5, and 14 in men and women are presented in Fig. [5](#Fig5){ref-type="fig"}. Both, men and women, showed a marked early decrease of NT-proBNP levels during the first 2 days of treatment. These levels further decreased in both sexes through day 5 and persisted through day 14. NT-proBNP changes were paralleled by increasing levels of cystatin-C in both sexes by day 5 and day 14. The levels of hs-troponin-T decreased through days 5 and 14 in men and women.Fig. 5Changes in hs-troponin-T, NT-proBNP, and cystatin-C by treatment and sex

Discussion {#Sec13}
==========

Marked or moderate early dyspnea improvement using the 7-item Likert scale was seen more often in women admitted for acute heart failure within the first 24 h, and persisted over the first 5 days. These improvements were not paralleled by the VAS-scale assessments. Similarly, general wellbeing, using the Likert scale over the first 5 days, improved significantly better in women, but this was not seen when the VAS wellbeing score was used. Other clinical outcome parameters were similar between men and women, and serelaxin was equally effective in men and women.

Dyspnea improvement by sex {#Sec14}
--------------------------

Dyspnea is a complex symptom in patients with acute heart failure. Patient-reported dyspnea relief is a clinically meaningful treatment goal because persistent dyspnea is associated with adverse outcome \[[@CR9], [@CR10]\]. It is advocated as a patient-relevant endpoint for heart failure trials by regulatory authorities \[[@CR11]\].

Therefore, our findings that women have a greater early dyspnea relief may be of clinical relevance. Although this difference could likely be explained by factors related to female sex, such as hypertension and heart failure with preserved ejection fraction (HFpEF), our multivariable analysis showed that female sex was an independent predictor of early dyspnea relief. No sex differences in dyspnea relief between men and women were found in a post hoc analysis of the PROTECT pilot study. However, patient numbers were small and no adjustments for preserved left ventricular ejection fraction were made \[[@CR12]\]. Comparable studies of early dyspnea relief in acute heart failure patients have not considered sex as covariate \[[@CR10]\].

The underlying cause of our findings is likely multifactorial. Remarkably, more intense dyspnea relief in women occurred despite using lower total IV and oral loop diuretic doses and less weight loss through day 5 in women compared to men, and comparable drops of NT-proBNP values were seen in both sexes. These findings can be explained pathophysiologically by a typical mechanism of cardiac decompensation in women, which is frequently caused by fluid redistribution and related to the higher proportion of HFpEF and hypertension among women \[[@CR13]\]. In this context, the slightly higher proportion of women being treated with intravenous nitrates during the first days of treatment could have favored the faster improvement of dyspnea in women. However, the absolute numbers of patients who were treated with intravenous inotrope/vasoactive medication were relatively low and it appears unlikely that this fully explains the differential dyspnea response by sex.

Theoretically, the higher rates of concomitant pulmonary disease, such as asthma, bronchitis, or COPD, in men, might have negatively affected dyspnea response in men. However, patients with relevant severity of these diseases were not included in the trial based on the exclusion criteria. Also, less diuretic treatment and less weight loss could be required in women to reach comparable outcome and better symptomatic relief. It is evidenced by trial results and registry data in acute heart failure that the overall outcome does not differ between men and women despite significantly lower diuretic doses and less absolute weight loss \[[@CR3], [@CR14]\]. It should be noted that all measured surrogates of congestion at baseline, such as edema, orthopnea, jugular venous pressure, dyspnea on exertion, and rales, were well balanced between men and women. Thus, it might be speculated that different symptom perception per se is responsible for the higher rates of moderate to marked dyspnea relief in women over men. Alternatively, underlying pathophysiological differences in fluid distribution may have translated to differences in symptoms. An acute cardiovascular, hypertensive type of failure has been proposed as subtype of acute heart failure \[[@CR13]\]. It is common in the elderly, patients with history of hypertension, and women, and is characterized by preserved left ventricular ejection fraction \[[@CR13]\]. In this type of heart failure, ventricular and vascular stiffness play important pathophysiological roles, with a vulnerability to any disorder of fluid balance, resulting in a rapid increase of vascular resistance, blood pressure and increased pulmonary pressure \[[@CR13]\]. Notably, the increase in pulmonary arterial pressure and the pulmonary capillary wedge pressure was previously identified as major determinants of dyspnea in an analysis of the hemodynamics of acute heart failure patients \[[@CR15]\]. Because data from community dwelling subjects have proven that women have greater aortic stiffening and lower total arterial compliance than men \[[@CR16]\], it might be speculated that rapid changes of intracardiac and intrapulmonary pressures as surrogates for dyspnea depend, to a greater extent, on changes of vascular volume load in women than in men. This could explain why early vasoactive and decongestive therapy might have more intense effects in women than in men, and that this could translate into differences in perceived dyspnea relief. These effects are more likely to be pronounced early during standard treatment, when the most intense reduction of vascular resistance and ventricular afterload is usually seen in acute heart failure patients \[[@CR15]\].

The question why marked or moderate early dyspnea improvement was seen more often in women using the 7-item Likert scale and not by the VAS-scale assessments could be due to the different aspects that are covered by the two different measurement scales. Notably, the Likert scale was used to assess early (6--24 h) dyspnea relief, whereas the VAS-scale was used to quantify persistent dyspnea relief by the change in VAS area under the curve (VAS AUC) through day 5, as specified in the study protocol \[[@CR17]\]. The MEASURE-HF study indicated that the Likert scale categories reflect initial improvement relative to the baseline status without capturing relevant improvement at later timepoints; contrarily, VAS scores of dyspnea improved steadily \[[@CR18]\]. Likert scale assessment emphasizes the change of perceived dyspnea compared to the most severe symptom sensation at baseline. The effect is more clearly measurable as an improvement on its categorical scale with higher initial symptom severity, but it is increasingly difficult to be captured as more time passes by. VAS scores capture the particular instantaneous state of dyspnea on a continuous scale individually at different timepoints. However, it is noteworthy that a trend towards higher change from baseline VAS score (mm) in women compared to men was detectable at the time points 6 and 12 h and after 1 day (*p* = 0.0933, *p* = 0.0518 and *p* = 0.0701, respectively) which also translated to a trend toward higher change from dyspnea VAS AUC (mm × h) from day 1 to day 5 (*p* = 0.0938) in women.

Serelaxin effects in men and women {#Sec15}
----------------------------------

Although relaxin is commonly known to exert various biologic effects in women during pregnancy \[[@CR19], [@CR20]\], data on sex-specific cardio-vascular effects are scarce. Debrah et al. demonstrated in a rat model that recombinant relaxin increases cardiac output and reduces arterial load in both male and female rats \[[@CR21]\]. In a recent subgroup analysis, it was shown that serelaxin was equally effective in men and women \[[@CR22]\]. The results of our interaction analyses confirm that sex does not modify the effects of serelaxin on dyspnea relief and/or any death- or rehospitalization-related outcomes in men and women.

Limitations {#Sec16}
-----------

All limitations of retrospective subgroup analyses apply to our study. No hypotheses regarding sex differences have been pre-specified, the ratio of men to women is unbalanced and, thus, our results could be biased. All results only have a hypothesis-generating character. The great majority of the women were white (i.e., 95%), so that results are not generalizable to black women, an increasing proportion of the heart failure population with high likelihood for poor outcomes. Also, validation of the VAS and the Likert scale in acute heart failure is largely based on data from men and lacking sex-specific validation.

Conclusion {#Sec17}
==========

Women exhibit better earlier dyspnea relief and improvement in general wellbeing as compared with men, even adjusted for age and left ventricular ejection fraction. However, in-hospital and post-discharge clinical outcomes were similar between men and women.

Appendix {#Sec18}
========

See Tables [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}.Table 5Interaction analysis of sex and treatment interaction (unadjusted) (*n* = 1161)Outcome*p* value for interaction^a^ sex by treatmentAll-cause death through day 1800.7229CV death through day 600.7151Days alive and out of hospital through day 600.2473CV death or HF/RF rehospitalization through day 600.7247RF rehospitalization through day 600.9933HF rehospitalization through day 600.8778Worsening heart failure through day 50.6764SCr increase of ≥0.3 mg/dL above baseline through day 50.0585Dyspnea VAS AUC to day 50.9228Time to moderately or markedly better dyspnea through day 5 (days)0.2050Dyspnea Likert scale moderately/marked better at 6, 12, and 24 h0.3869^a^Interaction *p* value comes from multiple linear regression models for continuous outcomes, logistic regression models for categorical outcomes, Cox proportional hazards models for time-to-event outcomes Table 6Interaction analysis of sex, treatment, and HF interaction (unadjusted) (*n* = 1091)Outcome*p* value for interaction^a^ sex by treatment*p* value for interaction^a^ sex by HFpEF*p* value for interaction^a^ HFpEF by treatment*p* value for interaction^a^ sex by treatment by HFDyspnea VAS AUC to day 50.47140.49870.24360.0945Dyspnea Likert scale moderately/marked better at 6, 12, and 24 h0.63010.14810.54620.2927Days alive and out of hospital through day 600.07900.07370.04880.0737CV death or HF/RF rehospitalization through day 600.79250.56820.93350.9726CV death through day 600.29610.15650.26850.1468HF rehospitalization through day 600.55820.95520.53300.4230RF rehospitalization through day 600.99471.00000.99700.9999All-cause death through day 1800.96610.38980.71600.7908Time to moderately or markedly better dyspnea through day 5 (days)0.78990.52040.28960.1543SCr increase of ≥0.3 mg/dL above baseline through day 50.06020.47210.84470.7312Worsening heart failure through day 50.45980.30900.08640.0319HFpEF vs. HFrEFSubjects with missing HF were omitted from the analysis^a^Interaction *p* value comes from multiple linear regression models for continuous outcomes, logistic regression models for categorical outcomes, Cox proportional hazards models for time-to-event outcomes
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